Eversept Partners LP Invests $556,000 in Scpharmaceuticals Inc (NASDAQ:SCPH)

Share on StockTwits

Eversept Partners LP acquired a new stake in Scpharmaceuticals Inc (NASDAQ:SCPH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 174,297 shares of the company’s stock, valued at approximately $556,000. Eversept Partners LP owned 0.94% of Scpharmaceuticals as of its most recent SEC filing.

Separately, SG Americas Securities LLC acquired a new stake in shares of Scpharmaceuticals in the first quarter valued at about $51,000. Institutional investors and hedge funds own 39.67% of the company’s stock.

SCPH traded up $0.06 during midday trading on Friday, reaching $7.08. 217 shares of the company’s stock were exchanged, compared to its average volume of 46,926. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.04 and a quick ratio of 6.04. The stock has a market capitalization of $132.13 million, a PE ratio of -4.45 and a beta of 0.84. The business’s 50-day moving average price is $6.08 and its 200 day moving average price is $4.05. Scpharmaceuticals Inc has a 1-year low of $2.44 and a 1-year high of $7.85.

Scpharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.10. As a group, analysts expect that Scpharmaceuticals Inc will post -1.85 EPS for the current fiscal year.

Several brokerages recently commented on SCPH. ValuEngine cut shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Zacks Investment Research cut shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th.

About Scpharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Read More: Cash Flow Analysis in Stock Selection

Institutional Ownership by Quarter for Scpharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.